Targeting VEGFR-2 with piperazine bridged indolin-2-one derivatives


ZENGİN M., Arafa R. K., TÜYLÜ KÜÇÜKKILINÇ Z. T., ÜNSAL TAN O.

Bioorganic Chemistry, cilt.174, 2026 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 174
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1016/j.bioorg.2026.109693
  • Dergi Adı: Bioorganic Chemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, Chimica, EMBASE
  • Anahtar Kelimeler: Cytotoxic effect, Indolin-2-one, Molecular docking, Piperazine, VEGFR-2 inhibition
  • Hacettepe Üniversitesi Adresli: Evet

Özet

As a key mediator of tumor angiogenesis, VEGFR-2 has emerged as a promising therapeutic target for combating cancer. In the present study, a series of 6-substituted-3-(4-(4-(substitutedphenyl/benzyl)piperazin-1-yl)benzylidene) indolin-2-one derivatives ( 2–24 ) were synthesized in good yields and structurally confirmed by IR, NMR, and HRMS analyses. Several compounds exhibited strong VEGFR-2 inhibition, with activities comparable to or exceeding that of sorafenib, but lower than sunitinib. Cytotoxicity assays against MCF-7 breast cancer cells revealed five derivatives ( 4 , 7 , 9 , 10 , and 12 ) more active than doxorubicin along with five additional compounds showing comparable potency. In contrast, the compounds displayed moderate cytotoxic activity against the MDA-MB-231 cell line and none showed significant toxicity toward MCF-10A normal breast epithelial cells. Mechanistic studies of compound 10 demonstrated G0/G1 phase arrest , apoptosis induction, and increased ROS generation , suggesting its potential as a selective and effective lead for breast cancer therapy.